Nektar Therapeutics News

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fin

NektarMay 2 12:00

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar

BenzingaApr 30 20:06

NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)

Yahoo FinanceApr 26 16:12

Nektar Therapeutics Receives Letter That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq Capital Market - Filing

To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business

BenzingaApr 18 05:16

NKTR, VERU and EGIO Among Mid-day Movers

Seeking AlphaApr 12 00:55

Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?

Yahoo FinanceApr 3 23:30

Nektar Therapeutics Is Worried About This – Should You Be Worried Too?

TipRanksMar 7 14:00

Nektar Therapeutics Is Maintained at Hold by Jefferies

Nektar Therapeutics Is Maintained at Hold by Jefferies

Dow JonesMar 6 22:54

Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1

Jefferies analyst Roger Song maintains Nektar Therapeutics (NASDAQ:NKTR) with a Hold and raises the price target from $0.5 to $1.

BenzingaMar 6 22:44

Nektar Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 13.64% Jefferies $0.5 → $1 Maintains Hold 11/20/2023 — JP Morgan Reinstates → Underweight 11/0

BenzingaMar 6 22:43

Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata

Nektar Therapeutics (NKTR) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata. The Phase 2b study will evaluate rezpe

MT NewswiresMar 6 05:04

Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating

Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating.

MT NewswiresMar 6 01:49

Nektar Therapeutics Announces Initiation Of Phase 2b Clinical Study Evaluating Rezpegaldesleukin In Patients With Severe To Very Severe Alopecia Areata

Nektar Therapeutics (NASDAQ:NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rez

BenzingaMar 5 22:09

Q4 2023 Nektar Therapeutics Earnings Call

Yahoo FinanceMar 5 20:19

Earnings Call: Nektar Therapeutics Unveils Drug Development Progress

InvestingMar 5 17:20

Earnings Call Summary | Nektar Therapeutics(NKTR.US) Q4 2023 Earnings Conference

The following is a summary of the Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript:Financial Performance:Nektar ended the year with a strong balance sheet, having $329.4 million in cash and

Futu NewsMar 5 12:13 · Conference Call

Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results

Yahoo FinanceMar 5 05:51

Nektar Therapeutics Q4 Loss Decreases, but Misses Estimates

RTTNewsMar 5 05:18

Nektar Therapeutics GAAP EPS of -$0.22 Misses by $0.01, Revenue of $23.89M Beats by $2.52M

Seeking AlphaMar 5 05:17

Nektar Therapeutics 4Q Rev $23.9M >NKTR

Nektar Therapeutics 4Q Rev $23.9M >NKTR

Dow JonesMar 5 05:15